The Pain Crises Everyone Called Growing Pains - Genetics clinical simulation case. A 9-year-old boy with a six-year history of episodic, agonizing burning...
Age: 9 • Gender: Male • Setting: Emergency Triage
Clinical Presentation & History
A 9-year-old boy with a six-year history of episodic, agonizing burning pain in his hands and feet, accompanied by recurrent unexplained fevers, recurrent post-exercise collapse, and progressive proteinuria. Multiple specialists have attributed his symptoms to rheumatic fever, juvenile idiopathic arthritis, and behavioral somatization. He is now in the resuscitation bay with an acute pain crisis and a low-grade fever following a soccer match. Yousef is a bright, articulate 9-year-old from a consanguineous Emirati family (parents are first cousins). His father has chronic kidney disease of unknown etiology on hemodialysis since age 38. An older brother, now 14, has unexplained proteinuria. A maternal uncle died in his 20s from cardiac complications of unclear cause. Yousef has missed an average of 35 school days per year due to his pain episodes, which have been triggered by heat, exertion, and febrile illness. He has been treated empirically with NSAIDs, gabapentin, and a brief course of corticosteroids without sustained relief. He describes the pain as 'hot needles and electric shocks' in his palms and soles that leaves him unable to walk.
Acute Resuscitation Milestones & Priorities
Clinical phases and key interventions encountered in this emergency module:
Triage: The Boy No One Believed
Confirmatory Pathway Testing
Renal and Cardiac Future Protection
Disposition, Family Cascade, and School Plan
High-Yield Clinical Pearls
Angiokeratomas in a 'swimming trunk' distribution plus episodic acroparesthesia in a child is pathognomonic suspicion for Fabry disease until proven otherwise — not 'growing pains' and not psychogenic.
Plasma α-galactosidase A activity and lyso-Gb3 are first-line biomarkers in males; confirm with GLA gene sequencing (including MLPA for large deletions) before committing to lifelong ERT.
ACE inhibitor renoprotection is indicated at any level of Fabry proteinuria, not deferred to 1 g/day as in non-Fabry CKD.
Enzyme replacement therapy (agalsidase alfa or beta) should be started in classic male pediatric Fabry patients regardless of eGFR to preserve podocytes and myocardium before irreversible fibrosis.
Carbamazepine is preferred over phenytoin or NSAIDs for chronic Fabry neuropathic pain prophylaxis; NSAIDs accelerate CKD.
Cascade screening is mandatory in X-linked Fabry: the mother is an obligate carrier, sisters have 50% risk, and the brother has 50% hemizygous risk — early identification saves renal and cardiac futures across the family.
Test Your Clinical Reasoning in Real Time
Step into the active clinician role for this case. Order diagnostic tests, analyze live laboratory panels, and navigate branching clinical decisions with real-time feedback.